close

Enter

Log in using OpenID

Bladder Cancer Therapeutics Market

embed
Bladder Cancer Therapeutics Market - Size,
Share, Growth, Outlook, and Opportunity
Analysis, 2018-2026
As per stats released by the World Cancer Research Fund International, around 430,000 new cases
of bladder cancer were diagnosed in 2012, with bladder cancer being the ninth-most common cancer.
The bladder holds urine before it leaves the body during urination. The disease in which cancerous
cells form in the tissues of the bladder is known as bladder cancer. There are three major types of
bladder cancer and are named on the basis of type of cells become cancerous (malignant).
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/239
According to the study of American Society of Clinical Oncology (ASCO), urothelial carcinoma
accounts for around 90%, squamous cell carcinoma accounts 4% and adenocarcinoma accounts 2%
of all bladder cancer. The remaining 4% bladder cancer includes other rare type of bladder cancer
viz. sarcoma and small cell anaplastic cancer.
There are different types of treatment followed by doctors, which are mostly dependent on the
patient’s preference for treatment and also based on type, possible side effects of the treatment
and stage of bladder cancer.
Increasing incidence rate, especially in developed regions fueling growth of bladder
cancer therapeutics market
As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder
cancer cases are observed in developed countries, with Belgium reporting the highest number of
bladder cancer cases.
As per stats released by Cancer Research UK—a charity involved in cancer research and
development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer
accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the
American Society of Clinical Oncology (ASCO), incidence rate of the disease has decreased by
around 12% in the U.K. in the recent past.
Report includes chapters which deeply display the following deliverable about industry :
• Bladder Cancer Therapeutics Market Research Objective and Assumption
• Bladder Cancer Therapeutics Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Bladder Cancer Therapeutics Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Bladder Cancer Therapeutics Market, By Regions
• Bladder Cancer Therapeutics Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Bladder Cancer Therapeutics Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Bladder Cancer Therapeutics Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Bladder Cancer Therapeutics Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
The major companies playing key role in bladder therapeutics market are Sanofi S.A., F.
Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers
Squibb, Allergan Inc, AVI Biopharma Inc., and AstraZeneca plc. Some are the major drugs
approved by Food and Drug Administration used for the treatment of bladder cancer are
Cisplatin, Nivolumab, Thiotepa, Atezolizumab, Doxorubicin Hydrochloride, Opdivo
(Nivolumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), and Tecentriq (Atezolizumab).
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/239
Bladder cancer therapeutics market taxonomy:
Global Market by Bladder Cancer Type
• Urothelial Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma
Global Market by Treatment Type
• Surgery
• Transurethral bladder tumor resection (TURBT)
• Cystectomy
• Urinary Diversion
• Chemotherapy
• Intravesical (local) Chemotherapy
• Systemic (whole body) Chemotherapy
• Immunotherapy
• Intravesical Therapy
• Interferon Therapy
• Radiation Therapy
Global Market by Test Type
•
•
•
•
•
Biopsy
Cystoscopy
Urine Cytology
Urinalysis
Bladder Ultrasound
Global Market by Gender
• Men
• Women
Global Market by Geography
•
•
•
•
•
•
North America
Europe
APAC
Latin America
Middle East
Africa
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
20   documents Email
Document
Category
Health and Medicine
Views
1
File Size
166 KB
Tags
bladder
1/--pages
Report inappropriate content